Chemoresistance of glioblastoma cancer stem cells - much more complex than expected

被引:252
作者
Beier, Dagmar [1 ]
Schulz, Joerg B. [1 ]
Beier, Christoph P. [1 ]
机构
[1] Rhein Westfal TH Aachen, Dept Neurol, Sch Med, D-52074 Aachen, Germany
关键词
glioblastoma; cancer stem cell; temozolomide; chemoresistance; BCNU; MALIGNANT GLIOMA-CELLS; NEWLY-DIAGNOSED GLIOBLASTOMA; TERM TEMOZOLOMIDE TREATMENT; REPAIR GENE MGMT; DNA-DAMAGE; MISMATCH REPAIR; SIDE POPULATION; SELF-RENEWAL; IN-VITRO; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE;
D O I
10.1186/1476-4598-10-128
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Glioblastomas (GBM) are a paradigm for the investigation of cancer stem cells (CSC) in solid malignancies. The susceptibility of GBM CSC to standard chemotherapeutic drugs is controversial as the existing literature presents conflicting experimental data. Here, we summarize the experimental evidence on the resistance of GBM CSC to alkylating chemotherapeutic agents, with a special focus on temozolomide (TMZ). The data suggests that CSC are neither resistant nor susceptible to chemotherapy per se. Detoxifying proteins such as O-6-methylguanine-DNA-methyltransferase (MGMT) confer a strong intrinsic resistance to CSC in all studies. Extrinsic factors may also contribute to the resistance of CSC to TMZ. These may include TMZ concentrations in the brain parenchyma, TMZ dosing schemes, hypoxic microenvironments, niche factors, and the re-acquisition of stem cell properties by non-stem cells. Thus, the interaction of CSC and chemotherapy is more complex than may be expected and it is necessary to consider these factors in order to overcome chemoresistance in the patient.
引用
收藏
页数:11
相关论文
共 94 条
[1]
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs [J].
Ashley, D. M. ;
Riffkin, C. D. ;
Lovric, M. M. ;
Mikeska, T. ;
Dobrovic, A. ;
Maxwell, J. A. ;
Friedman, H. S. ;
Drummond, K. J. ;
Kaye, A. H. ;
Gan, H. K. ;
Johns, T. G. ;
Hawkins, C. J. .
BRITISH JOURNAL OF CANCER, 2008, 99 (02) :294-304
[2]
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response [J].
Bao, Shideng ;
Wu, Qiulian ;
McLendon, Roger E. ;
Hao, Yueling ;
Shi, Qing ;
Hjelmeland, Anita B. ;
Dewhirst, Mark W. ;
Bigner, Darell D. ;
Rich, Jeremy N. .
NATURE, 2006, 444 (7120) :756-760
[3]
Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs:: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks [J].
Batista, Luis F. Z. ;
Roos, Wynand P. ;
Christmann, Markus ;
Menck, Carlos F. M. ;
Kaina, Bernd .
CANCER RESEARCH, 2007, 67 (24) :11886-11895
[4]
RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study [J].
Beier, Christoph P. ;
Schmid, Christina ;
Gorlia, Thierry ;
Kleinletzenberger, Christine ;
Beier, Dagmar ;
Grauer, Oliver ;
Steinbrecher, Andreas ;
Hirschmann, Birgit ;
Brawanski, Alexander ;
Dietmaier, Christopher ;
Jauch-Worley, Tanja ;
Koelbl, Oliver ;
Pietsch, Torsten ;
Proescholdt, Martin ;
Ruemmele, Petra ;
Muigg, Armin ;
Stockhammer, Guenther ;
Hegi, Monika ;
Bogdahn, Ulrich ;
Hau, Peter .
BMC CANCER, 2009, 9 :308
[5]
Temozolomide preferentially depletes cancer stem cells in glioblastoma [J].
Beier, Dagmar ;
Roehrl, Stefanie ;
Pillai, Deepu R. ;
Schwarz, Stefanie ;
Kunz-Schughart, Leoni A. ;
Leukel, Petra ;
Proescholdt, Martin ;
Brawanski, Alexander ;
Bogdahn, Ulrich ;
Trampe-Kieslich, Ariane ;
Giebel, Bernd ;
Wischhusen, Joerg ;
Reifenberger, Guido ;
Hau, Peter ;
Beier, Christoph P. .
CANCER RESEARCH, 2008, 68 (14) :5706-5715
[6]
CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles [J].
Beier, Dagmar ;
Hau, Peter ;
Proescholdt, Martin ;
Lohmeier, Annette ;
Wischhusen, Joerg ;
Oefner, Peter J. ;
Aigner, Ludwig ;
Brawanski, Alexander ;
Bogdahn, Ulrich ;
Beier, Christoph P. .
CANCER RESEARCH, 2007, 67 (09) :4010-4015
[7]
PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells [J].
Bleau, Anne-Marie ;
Hambardzumyan, Dolores ;
Ozawa, Tatsuya ;
Fomchenko, Elena I. ;
Huse, Jason T. ;
Brennan, Cameron W. ;
Holland, Eric C. .
CELL STEM CELL, 2009, 4 (03) :226-235
[8]
BLOUGH MD, 2010, NEURO ONCOL
[9]
O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines [J].
Bobola, MS ;
Silber, JR ;
Ellenbogen, RG ;
Geyer, JR ;
Blank, A ;
Goff, RD .
CLINICAL CANCER RESEARCH, 2005, 11 (07) :2747-2755
[10]
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies [J].
Brada, M ;
Judson, I ;
Beale, P ;
Moore, S ;
Reidenberg, P ;
Statkevich, P ;
Dugan, M ;
Batra, V ;
Cutler, D .
BRITISH JOURNAL OF CANCER, 1999, 81 (06) :1022-1030